BCC 2021 | Genomic assay performance: core needle biopsy vs. surgical resection samples

Miranda Kleijn, PhD, Agendia, Amsterdam, Netherlands, shares the findings of a comparative assessment of MammaPrint and BluePrint genetic assay results between core needle biopsy and surgical resection breast cancer samples. Core needle biopsy sampling has become increasingly important during the COVID-19 pandemic to accurately risk assess patients pre-operatively, so that limited resources can be prioritized for the most in need patients. When test performance was evaluated across specimen type, it was demonstrated that results were comparable regardless of specimen type. Turnaround time and index score distribution showed no meaningful difference between the core needle biopsy and surgical resection specimens. This interview took place during the 17th St. Gallen International Breast Cancer Conference.